Umbilical Cord Blood Stem Cell Banking
|P.A. 637 of 2006
H.B. 6291 – Rep. Glenn Steil
P.A. 638 of 2006
P.A. 639 of 2006
P.A. 635 of 2006
P.A. 636 of 2006
Five of the seven bills were signed by Governor Granholm on 1/3/07 with immediate effect. H.B. 6292 was vetoed by the Governor because of budget constraints. H.B. 6294 died in the Senate, for the same reason.
H.B. 6292 Provides a tax credit for individuals making a cash donation to cord blood stem cell banks. The tax credit would be capped at 50% of a cash donation up to $100 for a single filer and $200 for a joint filer.
H.B. 6293 Requires the Department of Community Health to develop and promote educational materials on the uses of cord blood stem cells, to enable the public to make informed decisions about the benefits of donating and storing cord blood.
H.B. 6294 Allocate $5 million from the 21st Century Jobs Trust Fund to the statewide network of cord blood stem cell banks in order to establish, operate and sustain.
H.B. 6295 Revise the definition of “life science” in the Michigan Strategic Fund Act to include umbilical cord blood research.
S.B. 1353 Lists the definitions used in the package of bills.
S.B. 1354 Requires the department to promote educational avenues on the uses of cord blood stem cells.
Most importantly, extracting umbilical cord blood stem cells does not harm the donor. After the birth of a baby, the cord is clamped and the doctor or midwife immediately draws out 2-5 ounces of blood from the cord. The umbilical cord and placenta are considered “medical waste” and are normally incinerated in the hospital. The blood is tested for safety and frozen in liquid nitrogen (- 196 C) indefinitely. These stem cells have the potential to be reprogrammed into other types of cells (pluripotence), for many uses. Cells originating from the patient’s own body will not reject the transplanted cells.
In contrast, stem cells extracted from an embryo always result in the destruction of that embryo. When implanted in the receiving subject, the embryonic stem cells are rejected as foreign bodies and have a tendency to grow tumors. To date there has been a lot of hype, but no clinical trials and no therapies produced by embryonic stem cells.
S.B. 1353-4 were introduced on 6/29/06 and referred to the Senate Health Policy Committee. On 11/29/06, they were reported out of the Senate Health Policy Committee, 5-0. They were passed on the Senate floor 11/30/06, 36-0. The House passed the bills on 12/14/06 with a vote of 107-0.